Abstract
The New Zealand Meningococcal Vaccine Strategy aims to end the devastating 14-year epidemic of B:4:P1.7b,4 group B meningococcal disease in New Zealand through a mass immunisation programme to all under 20 year olds using a tailor-made vaccine (MeNZB). This paper describes the scientific rationale, development, and key components of the New Zealand Meningococcal Vaccine Strategy. A summary of the efficacy and safety data of existing outer membrane vesicle group B meningococcal vaccines is included as these data critically support the Strategy.
- b,
- disease
- factors
- humans,
- immunization
- infections,
- meningitidis,
- meningococcal
- neisseria
- new
- outbreaks,
- population
- postmarketing,
- product
- programs,
- risk
- serogroup
- surveillance,
- vaccines,
- zealand,
Users
Please
log in to take part in the discussion (add own reviews or comments).